Oral Type 2 Diabetes Unmet Needs provides brand executives with a quantitative market analysis of critical gaps in the market for oral diabetes medications. It also identifies the areas that represent US endocrinologists’ and primary care providers’ largest demands. The market research report’s data analysis identifies the level of satisfaction for existing oral type 2 diabetes brands among key clinical attributes, such as efficacy, safety and tolerability.
The current market for oral diabetes medications presents physicians with many viable options to treat patients across the disease severity spectrum.
Even given these options, a significant percentage of endocrinologists still aren’t satisfied with the available therapies. This leaves significant gaps in the market for oral type 2 diabetes treatments.
Oral Type 2 Diabetes Unmet Needs contains healthcare providers’ expectations for seven oral type 2 diabetes pipeline therapies. These data also show pipeline drugs’ superiority, parity, and inferiority for specific clinical attributes.
Overview of Oral Type 2 Diabetes Unmet Needs
Though endocrinologists have powerful options to treat type 2 diabetes, the HCPs surveyed for Oral Type 2 Diabetes Unmet Needs identify key market gaps in the current clinical landscape. These market gaps are what lead to some significant ambivalence among HCPs about their overall treatment armamentarium.
While current oral type 2 diabetes treatments meet physicians’ highest priority needs, such as efficacy and safety. Some, however, are just barely doing so.
Clinical attributes such as market access for critical drugs and manufacturer support leave some endocrinologists and primary care providers wanting better solutions. Additionally, dosing and tolerability for current oral diabetes medications leave some endocrinologists waiting for new alternatives.
The market insights contained in Oral Type 2 Diabetes Unmet Needs emphasize the biggest market gaps and identify current pipeline therapies that aim to fulfill physicians’ unmet needs. This strategy guide also identifies which pipeline therapies will compete most significantly against existing oral diabetes medications within these areas of highest clinical need.
Clinical Attributes Analyzed
- Access
- Dosing
- Efficacy
- Safety
- Support
- Tolerability
Pipeline Treatments Analyzed
- Oral Insulin (ORMD-0801)
- Sotagliflozin
- Bexangliflozin
- Prusogliptin
- Imeglimin
Strategic Questions Answered about Unmet Needs for Oral Type 2 Diabetes Medications
- Physician Satisfaction: How satisfied are physicians with the current oral type 2 diabetes treatment armamentarium?
- Gap Analysis: Where are the biggest unmet needs among current oral diabetes medications in efficacy, safety, dosing, tolerability, access, and support?
- Pipeline Expectations: How do physicians expect pipeline therapies to fill current gaps in efficacy, safety, dosing, tolerability, access, and support?
Summary of Strategic Insights around Type 2 Diabetes Unmet Needs
- HCPs expect Sotagliflozin to be very similar to other available options. This is likely because they already have a few SGLT2s and expect it to be a “me-too” medication.
- While there are low levels of dissatisfaction with current oral type 2 diabetes options, more than half of HCPs are ambivalent with their current armamentarium.
- There is some familiarity for oral insulin and most HCPs expect it to have superior efficacy to the current available oral diabetes medications.
Benefits of Purchasing Oral Type 2 Diabetes Unmet Needs
- Cost-efficient data on HCPs’ oral type 2 diabetes unmet needs to guide commercial decisions, launch strategy, and brand positioning.
- Insights about the greatest areas of need within the current oral type 2 diabetes market gathered directly from in-depth interviews and surveys of more than 155 endocrinologists and primary care providers.
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s type 2 diabetes strategist for 1-year.
Table of Contents
Executive Summary – 5
Research Methodology: Robust Insights from US Endocrinologists – 6
The Strategic Six: Key Insights About Unmet Needs in the T2D Marketplace – 7
Gap Analysis of T2D Clinical Needs – 8
Unmet Needs Landscape – 9
- Satisfaction with Current T2D Armamentarium – 10
- Clinical Attributes with Highest Satisfaction – 11
- Clinical Attributes with Highest Ambivalence – 12
- Clinical Attributes with Highest Dissatisfaction – 13
- Importance of Attributes in Rx Decisions – 14
Brand Alignment with Unmet Needs – 15
- Brands Best Aligned with Efficacy Needs – 16
- Brands Best Aligned with Safety Needs – 17
- Brands Best Aligned with Tolerability Needs – 18
- Brands Best Aligned with Dosing Needs – 19
- Brands Best Aligned with Access Needs – 20
- Brands Best Aligned with Support Needs – 21
Pipeline Alignment with Unmet Needs – 22
- Pipeline Product Familiarity – 23
Oral Insulin (ORMD-0801) Competitive Outlook – 24
- Oral Insulin Superiority Expectations – 25
- Oral Insulin Parity Expectations – 26
- Oral Insulin Inferiority Expectations – 27
Sotagliflozin Competitive Outlook – 28
- Sotagliflozin Superiority Expectations – 29
- Sotagliflozin Parity Expectations – 30
- Sotagliflozin Inferiority Expectations – 31
Bexagliflozin Competitive Outlook – 32
- Bexagliflozin Superiority Expectations – 33
- Bexagliflozin Hydrochloride Parity Expectations – 34
- Bexagliflozin Inferiority Expectations – 35
Prusogliptin Competitive Outlook – 36
- Prusogliptin Superiority Expectations – 37
- Prusogliptin Parity Expectations – 38
- Prusogliptin Inferiority Expectations – 39
Imeglimin Competitive Outlook – 40
- Imeglimin Superiority Expectations – 41
- Imeglimin Parity Expectations – 42
- Imeglimin Inferiority Expectations – 43
Contact – 44
